drugset / Trial / NCT01349725
A Safety Study of ARRY-502 in Healthy Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
This is a Phase 1 study, involving a 14-day dosing period, designed to test the safety of investigational study drug ARRY-502 in healthy subjects. Approximately 32 healthy subjects from the United States will be enrolled in this study.
Timeline
- Start
- 2011-05
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARRY-502 | Small molecule | — | Oral |
Indications
No indication recorded.